DNA methylation mutations and chromatin/histone modifications belong to epigenetic modifiers. DNMT3A encodes an epigenetic regulator and mediates de novo methylation of CpG dinucleotides and are seen in approximately 20% of AML patients with normal karyotype. This mutation tends to shorten overall survival (14,37). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.